Nystatin: Difference between revisions
Elcatracho (talk | contribs) |
|||
| (4 intermediate revisions by 4 users not shown) | |||
| Line 1: | Line 1: | ||
==Administration== | ==Administration== | ||
*Type: Antifungal | *Type: [[Antifungal]] | ||
*Dosage Forms: | *Dosage Forms: | ||
*Routes of Administration: | *Routes of Administration: | ||
| Line 9: | Line 9: | ||
==Adult Dosing== | ==Adult Dosing== | ||
*Oral | ===[[Candidiasis]]=== | ||
*Oral candidiasis | |||
**4-6 mL PO QID of 100,000U/mL until 48 hrs after symptoms resolve | **4-6 mL PO QID of 100,000U/mL until 48 hrs after symptoms resolve | ||
*Intestinal candidiasis | *Intestinal candidiasis | ||
| Line 15: | Line 16: | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
===Oral [[candidiasis]]=== | |||
*Premature neonates: | |||
**1 mL PO QID of 100,000 U/mL until 48 hrs after symptoms resolve | |||
*Infants: | |||
**2 mL PO QID of 100,000 U/mL until 48 hrs after symptoms resolve | |||
*Children: | |||
**4-6 mL PO QID of 100,000 U/mL until 48 hrs after symptoms resolve | |||
==Special Populations== | ==Special Populations== | ||
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: C | *[[Drug Ratings in Pregnancy|Pregnancy Rating]]: C | ||
*[[Lactation risk categories|Lactation risk]]: Safe | *[[Lactation risk categories|Lactation risk]]: Safe | ||
===Renal Dosing=== | ===Renal Dosing=== | ||
*Adult: not defined | *Adult: not defined | ||
| Line 32: | Line 41: | ||
==Adverse Reactions== | ==Adverse Reactions== | ||
===Serious=== | ===Serious=== | ||
*Hypersensitivity | *Hypersensitivity reaction | ||
===Common=== | ===Common=== | ||
*Nausea / Vomiting | *[[Nausea]] / [[Vomiting]] | ||
*Diarrhea | *[[Diarrhea]] | ||
*Abdominal | *[[Abdominal pain]] | ||
==Pharmacology== | ==Pharmacology== | ||
| Line 50: | Line 59: | ||
==See Also== | ==See Also== | ||
*[[Antifungals]] | |||
*[[Fungal infections]] | |||
==References== | ==References== | ||
<references/> | <references/> | ||
[[Category: | [[Category:Pharmacology]] | ||
[[Category:ID]] | |||
Latest revision as of 03:17, 8 March 2021
Administration
- Type: Antifungal
- Dosage Forms:
- Routes of Administration:
- PO
- Topical
- Vaginal
- Common Trade Names: Nystop, Nyamyc
Adult Dosing
Candidiasis
- Oral candidiasis
- 4-6 mL PO QID of 100,000U/mL until 48 hrs after symptoms resolve
- Intestinal candidiasis
- 1-2 tabs (500,000 U) PO TID until 48 hrs after symptoms resolve
Pediatric Dosing
Oral candidiasis
- Premature neonates:
- 1 mL PO QID of 100,000 U/mL until 48 hrs after symptoms resolve
- Infants:
- 2 mL PO QID of 100,000 U/mL until 48 hrs after symptoms resolve
- Children:
- 4-6 mL PO QID of 100,000 U/mL until 48 hrs after symptoms resolve
Special Populations
- Pregnancy Rating: C
- Lactation risk: Safe
Renal Dosing
- Adult: not defined
- Pediatric: not defined
Hepatic Dosing
- Adult: not defined
- Pediatric: not defined
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- Hypersensitivity reaction
Common
Pharmacology
- Half-life: unknown
- Metabolism: CYP450
- Excretion: Feces
Mechanism of Action
- Increases cell membrane permeability by binding to sterols